Key terms
About ABCL
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ABCL news
Apr 17
4:55am ET
AbCellera management to meet with Truist
Apr 15
7:50am ET
AbCellera management to meet with Truist
Mar 11
9:14am ET
AbCellera gets upfront payment for collaboration with Biogen for antibodies
Feb 24
10:11am ET
Peter Thiel Retires from AbCellera Board, Dr. Andrew Lo Steps In
Feb 23
7:33am ET
Piper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Feb 22
6:59am ET
AbCellera upgraded to Buy at Benchmark after R&D progress
Feb 22
6:17am ET
AbCellera upgraded to Buy from Hold at Benchmark
Feb 22
12:16am ET
AbCellera Biologics: A Strong Buy on Robust Pipeline and Solid Financial Outlook
Feb 21
8:23am ET
AbCellera price target lowered to $17 from $21 at Stifel
Feb 21
8:14am ET
Stifel Nicolaus Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Feb 21
7:31am ET
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL), Teladoc (TDOC) and Alnylam Pharma (ALNY)
Feb 20
9:30pm ET
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and AbCellera Biologics (ABCL)
Feb 20
4:47pm ET
AbCellera Biologics Reviews 2023 Financial Performance
Feb 20
4:07pm ET
AbCellera reports FY23 EPS (51c), consensus (47c)
No recent press releases are available for ABCL
ABCL Financials
Key terms
Ad Feedback
ABCL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ABCL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range